logo
Bill seeks $55 million for shared health education space at UND

Bill seeks $55 million for shared health education space at UND

Yahoo05-02-2025

Feb. 5—GRAND FORKS — Physicians and University of North Dakota administrators testified Monda in support of a bill allocating $55 million to build out the university's medical school facilities.
SB 2286
, introduced Jan. 20, would cover more than half of the cost of the three-story, 95,000-square-foot addition to the School of Medicine and Health Sciences, Dean Marjorie Jenkins told Senate lawmakers at an education committee meeting.
The bill's four sponsors — Reps. Gretchen Dobervich and Jon Nelson and Sens. Tim Mathern and Robert Erbele — all serve on the medical school's advisory council.
If the funding is approved, the university would look to consolidate several programs, including the entire College of Nursing and Professional Disciplines, under one roof in the new Health Professions Collaborative Facility.
"We're bringing the nurses, the doctors, the (physical therapy) people — the whole gamut — together," Mathern, D-Fargo, told lawmakers.
He was one of several proponents who said the shared space would create new opportunities for collaboration and interdisciplinary training between students in health care disciplines.
Administrators in particular emphasized a planned expansion of the university's simulation education center, which allows students studying medicine and related fields to practice real-world medical scenarios.
"The limit of what we have now is we don't have the capacity to do immersive, in-patient scenarios, like emergency rooms," Jenkins told the Herald. "That's where many of our students, especially those in rural areas, will be working."
Nursing Dean Maridee Shogren said new simulation facilities would allow for more shared research between health care disciplines, particularly simulation research.
Right now, she said, most simulation research is narrowly focused.
"We can be among the first institutions in the nation to look at simulation research across multiple disciplines," Shogren said.
The addition would replace space at the aging Columbia Hall and Nursing Buildings, both of which are in critically poor condition, according to a regular Facility Condition Assessment commissioned by the university.
The Nursing Building, built in 1976, needs $12.7 million in deferred maintenance, per the latest estimates from university facilities; Columbia Hall, on the other hand, is set to be torn down after the city fire marshals told the university it needed to either demolish the building or overhaul it to the tune of more than $48 million.
Jenkins said the addition would cost around $95 million, $40 million of which would be covered by donor contributions.
Finance and Operations Vice President Karla Mongeon-Stewart confirmed that figure to the Herald on Thursday; previous versions of the project, including for a separate facility, were previously pegged between $80 to $119 million.
SB 2286 also orders legislative management to examine "the funding necessary to provide education and internships statewide for all programs" in the Health Professions addition.
Jenkins said the study was meant to "optimize" the new space and show legislators it served the whole state's health care needs, particularly rural areas.
She told the Herald it was a way to show the Legislature its "return on investment," citing recent efforts to defund the medical school including
a resolution introduced last week
that would eliminate the constitutional statewide property tax levy of one mil received by the med school.
Several practicing physicians and representatives from the North Dakota Hospital Association and Altru Health System also spoke in favor or provided written testimony supporting the bill.
Funding for the addition was one of two large capital projects for which UND is seeking funding this legislative session.
The State Board of Higher Education included the university's other request, some $56 million for the second phase of a planned STEM complex, in the higher ed system's budget proposal, but not the Health Professions addition.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Yahoo

time2 days ago

  • Yahoo

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention. Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston Convention & Exhibition Center The Company's lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The Company is currently conducting a Phase 2 clinical study SKNJCT-003 in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President (610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

America might finally make childbirth free—and moms could be the biggest winners
America might finally make childbirth free—and moms could be the biggest winners

Yahoo

time2 days ago

  • Yahoo

America might finally make childbirth free—and moms could be the biggest winners

'This is how much it costs to give birth in America: $44,318.41.' That was the now-viral TikTok from a mom just days postpartum, scrolling through the itemized bill at home. Her insurance only covered $20,353.62—despite paying $2,500 a month for coverage for her family of five. This mom's story isn't an outlier. According to the Peterson-KFF Health System Tracker, privately insured families in the U.S. pay an average of $3,000 out-of-pocket for childbirth on average—just for having a baby. By 'choosing' to have a baby with a midwife in a birth center, I personally had to pay a $10k fee upfront. (Wanting midwifery care in a calm setting for my super fast labors didn't feel like a choice, but in America, it is.) Moms bear so many burdens for having babies. And one devastating cost that sets so many families back financially when they're just beginning life together is the price of childbirth, even with insurance. We're talking million-dollar NICU bills. $50k c-section charges. A financial punishment for doing the most critical work in a country: bringing the next generation of citizens into the world. But that may soon change. A bipartisan group of senators has introduced a bill that could be a game-changer for millions of American families. The Supporting Healthy Moms and Babies Act (S.1834) was announced on May 21, 2025, and aims to eliminate all out-of-pocket costs related to prenatal care, childbirth, and postpartum services for those with private health insurance. The bill's sponsors—Sens. Cindy Hyde-Smith (R-MS), Tim Kaine (D-VA), Josh Hawley (R-MO), and Kirsten Gillibrand (D-NY)—say the legislation is about protecting families from being buried in medical debt at one of the most vulnerable times in life. 'Bringing a child into the world is costly enough without piling on cost-share fees that saddle many mothers and families with debt,' Sen. Hyde-Smith said in a statement announcing the legislation. 'By relieving financial stresses associated with pregnancy and childbirth, hopefully more families will be encouraged to embrace the beautiful gift and responsibility of parenthood.' A companion bill is expected in the House, led by Rep. Jared Golden (D-ME), who told Vox, 'This idea is simple and powerful: Pregnancy and childbirth are normal parts of family life. So, insurance companies should treat it like the routine care it is and cover the cost—not stick people with huge medical bills.' While the average out-of-pocket cost is around $3,000, the financial burden can be far worse for many: 17% of privately insured moms face bills over $5,000 1% are hit with bills exceeding $10,000 17.5% of women with private insurance report problems paying medical bills Nearly 9% say they couldn't pay them at all These numbers are not just statistics—they represent real parents delaying care, going into debt, or struggling to recover financially in the fragile weeks after childbirth. If passed, the bill would expand the list of 'essential health benefits' under the Affordable Care Act to include full-spectrum maternity care. Medicaid already covers these services in full, and that's how 41% of births in the U.S. are paid for. But for the 178 million people on private insurance plans? Birth is still a budget-buster. The new legislation would require private insurers to pick up the tab. That means: Prenatal care (including appointments and ultrasounds) Labor and delivery Hospital stays Postpartum recovery and mental health care Neonatal and perinatal services Lactation support The estimated premium hike to cover it all? About $30 per year, according to Lawson Mansell, policy analyst at the Niskanen Center, who conducted the cost modeling for the bill. Mansell told Vox this proposal is the simplest way, on an administrative level, to make birth free. Related: Too many U.S. moms are in debt from giving birth. They deserve better. Beyond the financial relief, this bill has the potential to improve health outcomes for moms and babies. Research backs this up: A report by the Washington State Office of the Insurance Commissioner found that eliminating cost-sharing for prenatal services is associated with improved maternal and infant outcomes, including fewer preterm births and higher birth weights. So in addition to relieving the stress families face, covering prenatal care fully makes it more likely that moms actually get it. Another study published in BMC Public Health linked removing financial barriers under the Affordable Care Act to increased use of preventive care, such as mammography and Pap tests. While the study focused on these services, the findings suggest that eliminating financial barriers can encourage timely and consistent healthcare utilization. The bill's sponsors come from across the political spectrum—and so do its supporters. Everyone from the American Medical Association and the American College of Obstetricians and Gynecologists to anti-abortion groups like Americans United for Life and Susan B. Anthony Pro-Life America have voiced support. Even Planned Parenthood Action Fund commented they 'generally supports legislation to make the cost of maternal health care and parenting more affordable.' Related: The cost of giving birth is getting more expensive—and some families are getting hit with childbirth debt If the bill becomes law, the financial landscape of pregnancy would change dramatically—especially for those in the 'missing middle': families who earn too much for Medicaid but not enough to easily afford thousands in delivery fees. It would also offer immediate relief for parents managing multiple financial burdens at once: high rent, unpaid leave, child care costs, student loans. You know, new motherhood. Call your representatives. Especially if you have private insurance and have ever been slammed with a delivery bill. You can find contact info at and Share your story. Lawmakers have said constituent birth bill stories played a big role in shaping this legislation. Talk about it on social. If your childbirth costs shocked you, say so. Use hashtags like #MakeBirthFree and tag your reps. This moment is historic not just because it's bipartisan, but because it signals a new kind of family policy thinking: one where moms aren't expected to 'figure it out' in isolation, one giant bill at a time. As Yuval Levin of the American Enterprise Institute put it in a policy brief, 'Substantively and symbolically, bringing the out-of-pocket health care costs of childbirth to zero is an ambitious but achievable starting point for the next generation of pro-family policies.' Whether you're pregnant now or years past it, you probably remember your hospital bill—and you definitely remember how it made you feel. Exhausted. Angry. Maybe even ashamed. This new bill says: No more. And moms deserve that. Sources: Family-Friendly Policies for the 119th Congress. February 2025. AEI. Family-Friendly Policies for the 119th Congress. America might finally make childbirth free. May 2025. Vox. America might finally make childbirth free. Americans United for Life Applauds Bipartisan Innovative Policy Proposal. May 2025. America United for Life. Americans United for Life Applauds Bipartisan Innovative Policy Proposal to Make Maternal Healthcare More Affordable. AMA advocacy to improve maternal health. May 2025. AMA. AMA advocacy to improve maternal health. Impact of removing cost sharing. 2019. BMC Public Health. Impact of removing cost sharing under the affordable care act (ACA) on mammography and pap test use. New bipartisan proposal would remove childbirth costs. May 2025. Niskanen Center. New bipartisan proposal would remove childbirth costs and confusion for parents. Characteristics of Mothers by Source of Payment for the Delivery. May 2023. CDC. Characteristics of Mothers by Source of Payment for the Delivery: United States, 2021. About the Affordable Care Act. Us Department of Health an Human Services. About the Affordable Care Act. Out-of-pocket medical bills childbirth. National Library of Medicine. Out-of-pocket medical bills from first childbirth and subsequent childbearing. The Association of Childbirth with Medical Debt. National Library of Medicine. The Association of Childbirth with Medical Debt in the USA, 2019–2020. Sentators introduce bill to ease financial burden of pregnancy. Cindy Hyde-Smith. SENATORS INTRODUCE BIPARTISAN BILL TO EASE THE FINANCIAL BURDEN OF PREGNANCY, CHILDBIRTH. Women who Give Birth Incur Nearly $19,000 in Additional Health Costs. KFF. Women who Give Birth Incur Nearly $19,000 in Additional Health Costs, Including $2,854 More that They Pay Out of Pocket.

Nvidia, quantum computing, Tesla robotaxi: Trending Tickers
Nvidia, quantum computing, Tesla robotaxi: Trending Tickers

Yahoo

time2 days ago

  • Yahoo

Nvidia, quantum computing, Tesla robotaxi: Trending Tickers

Nvidia (NVDA) is edging higher Wednesday morning, now within earshot of its record high stock price of $149.43 reached in January 2025. CEO Jensen Huang will deliver the keynote address at the 2025 VivaTech conference in Paris, France. Shares of quantum computing companies D-Wave Quantum (QBTS), Rigetti Computing (RGTI), and IonQ (IONQ) are rising as Huang grows more bullish on the industry, believing quantum computing is nearing an inflection point where it is capable of solving real world problems. Tesla (TSLA) CEO and SpaceX ( founder Elon Musk expresses his regret about his public spat with President Trump ahead of his EV company's robotaxi launch in Austin, Texas. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store